Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

By The Northwire Desk — AI Analysis Dec 24, 2025 · 08:30 MDMA · 0.11 Pharmala Biotech Holdings Inc.
MDMA · Price

Executive Summary

  • PharmAla Biotech Holdings filed its audited FY 2025 financial statements and unaudited Q1 2026 interim consolidated financial statements.
  • Customer deposits grew to $433 k in Q1 2026, reflecting increased demand for LaNeo™ MDMA and supporting future clinical‑trial revenue.
  • The company announced a short‑form prospectus filing, secured an Australian lending partner, and outlined plans to commence Phase 2a/b trials in Australia during fiscal 2026.

Key Details

  • Financial Filings: Audited FY 2025 statements and unaudited Q1 2026 interim consolidated financial statements are now publicly available on the Company’s website and SEDAR+.
  • Customer Deposits – Year End 2025: $276 k (up $150 k YoY, offset by $83 k recognized revenue).
  • Customer Deposits – Q1 2026: $433 k (up $225 k QoQ, offset by $68 k recognized revenue).
  • Deposit Structure: Typically 50 % of total contract value; recognized as revenue when product is shipped after regulatory permits are obtained.
  • Operational Milestones: Filed short‑form prospectus; secured Australian lending partner; expanded clinical‑trial revenue pipeline.
  • Future Plans: Target to commence Phase 2a/b clinical trial in Australia later in fiscal 2026.
  • Management Comments: CEO Nick Kadysh highlighted momentum in novel molecule development and growing demand for LaNeo™ MDMA, citing recent reimbursement approvals by Australian private insurers and the Department of Veterans Affairs. CFO Will Avery emphasized that the new financing and deposit growth will fund upcoming trial work.

Notable Quotes

“Commencing in late 2025 and continuing into Q1 2026 we have taken major steps towards the development of our novel molecules… with the goal of commencing our Phase 2a/b clinical trial in Australia.” – Nick Kadysh, CEO

“We have filed our short‑form prospectus, secured a lending partner in Australia and have grown our clinical trial revenue pipeline… all of which will help us to fund our clinical trial and development work.” – Will Avery, CFO

Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property May 13, 2026 · 08:30

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations